A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Inclusion Criteria Concurrent Medication: Required: Primary CMV treatment. Patients must have: AIDS. Active CMV retinitis. At least one photographable lesion of one-quarter or more optic disc area in size. Undergoing primary treatment for CMV retinitis that is not contraindicated with MSL 109. Visual acuity in at least one eye of 3 or more letters on Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart at 1 meter distance ( Snellen equivalent 5/200 ). Note: Exceptions may be made if visual acuity impairment is possibly reversible and there is at least light perception in that eye. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Retinal detachment not scheduled for surgical repair. Media opacity that precludes visualization of the fundus. Active medical problems sufficient to hinder study compliance. Concurrent Medication: Excluded: IVIG. CMV immune globulin ( CMVIG ). Interferon alpha. Interferon gamma. Interleukin-2 ( IL-2 ). Drug or alcohol abuse sufficient to hinder study compliance.